Conjugate comprises: a releasable cell alpha-amanitin peptide linked to a matrix metalloproteinase (MMP)-cleavable linker that is cleavable by a matrix; and a dendrimer or other carrier to which the releasable alpha-amanitin peptide and cleavable linker are conjugated. The amanitin peptide is releasable from the conjugate when contacted with MMP that cleaves the cleavable linker.
USE – The conjugate is useful: for treating cancer, tumor or neoplasm, where the cancer, tumor or neoplasm is prostate cancer, uterine cancer, breast cancer, mammary tumor, ovarian cancer, squamous cell carcinoma, basal cell carcinoma, glioblastoma, lymphoma, colorectal cancer, gastric cancer, hepatocellular carcinoma or pancreatic cancer (all claimed). Test details are described but no results given.
ADVANTAGE – The conjugate provides tumor treatment with double selectivity for tumor or cancer cells.